Recurrent exon-deleting activating mutations in AHR act as drivers of urinary tract cancer
暂无分享,去创建一个
E. Cuppen | E. Kalkhoven | B. Faltas | P. Priestley | C. Shale | N. Besselink | E. Kuijk | Judith M. Vlaar | Anouska Borgman | Denise Westland
[1] Jean-Claude Laprie,et al. Trend Analysis , 1996, The SAGE Encyclopedia of Research Design.
[2] Yuyan Zhu,et al. TRIB3 Promotes the Malignant Progression of Bladder Cancer: An Integrated Analysis of Bioinformatics and in vitro Experiments , 2021, Frontiers in Genetics.
[3] E. Cuppen,et al. Molecular characterization reveals genomic and transcriptomic subtypes of metastatic urothelial carcinoma , 2021, bioRxiv.
[4] Raphael Gottardo,et al. Integrated analysis of multimodal single-cell data , 2020, Cell.
[5] Jose Espejo Valle-Inclan,et al. GRIDSS2: comprehensive characterisation of somatic structural variation using single breakend variants and structural variant phasing , 2021, Genome Biology.
[6] S. Monti,et al. How the AHR Became Important in Cancer: The Role of Chronically Active AHR in Cancer Aggression , 2020, International journal of molecular sciences.
[7] Daniel L. Cameron,et al. Unscrambling cancer genomes via integrated analysis of structural variation and copy number , 2020, bioRxiv.
[8] A. Lenis,et al. Bladder Cancer: A Review. , 2020, JAMA.
[9] Andrew Menzies,et al. Extensive heterogeneity in somatic mutation and selection in the human bladder , 2020, Science.
[10] F. Radvanyi,et al. Identification of new driver and passenger mutations within APOBEC-induced hotspot mutations in bladder cancer , 2020, Genome Medicine.
[11] Assessment of Luminal and Basal Phenotypes in Bladder Cancer , 2020, Scientific Reports.
[12] R. Huddart,et al. ERDAFITINIB in locally advanced or metastatic urothelial carcinoma (mUC): Long-term outcomes in BLC2001. , 2020 .
[13] A. McCluskey,et al. The aryl hydrocarbon receptor (AhR) as a breast cancer drug target , 2019, Medicinal research reviews.
[14] Ashley M. Laughney,et al. Urothelial organoids originating from Cd49fhigh mouse stem cells display Notch-dependent differentiation capacity , 2019, Nature Communications.
[15] A. Atala. Re: Mouse and Human Urothelial Cancer Organoids: A Tool for Bladder Cancer Research. , 2019, The Journal of urology.
[16] Z. Mo,et al. Single-Cell Transcriptomic Map of the Human and Mouse Bladders. , 2019, Journal of the American Society of Nephrology : JASN.
[17] R. Huddart,et al. Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. , 2019, The New England journal of medicine.
[18] A. Hanberg,et al. Histopathological features of the proper gastric glands in FVB/N-background mice carrying constitutively-active aryl-hydrocarbon receptor , 2019, BMC Gastroenterology.
[19] Harry Begthel,et al. Mouse and human urothelial cancer organoids: A tool for bladder cancer research , 2019, Proceedings of the National Academy of Sciences.
[20] S. Szymańska,et al. On histOpathOlOgical features , 2019 .
[21] A. Vlahou,et al. Proteome‐based classification of Nonmuscle Invasive Bladder Cancer , 2019, International journal of cancer.
[22] S. Sleijfer,et al. Pan-cancer whole-genome analyses of metastatic solid tumours , 2018, bioRxiv.
[23] Vinicius S. Chagas,et al. Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer , 2018, Cell.
[24] X. Coumoul,et al. AhR signaling pathways and regulatory functions , 2018, Biochimie open.
[25] S. Saxena,et al. Overexpression of COX2 indicates poor survival in urothelial bladder cancer. , 2018, Annals of diagnostic pathology.
[26] Joseph G Ibrahim,et al. Heavy-tailed prior distributions for sequence count data: removing the noise and preserving large differences , 2018, bioRxiv.
[27] Chris Berdik. Unlocking bladder cancer , 2017, Nature.
[28] Icgc,et al. Pan-cancer analysis of whole genomes , 2017, bioRxiv.
[29] Role of the aryl hydrocarbon receptor in carcinogenesis and potential as an anti-cancer drug target , 2017, Archives of Toxicology.
[30] Yitong Li,et al. Structural hierarchy controlling dimerization and target DNA recognition in the AHR transcriptional complex , 2017, Proceedings of the National Academy of Sciences.
[31] Mauro J. Muraro,et al. A Single-Cell Transcriptome Atlas of the Human Pancreas , 2016, Cell systems.
[32] W. Huber,et al. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.
[33] C. Mendelsohn,et al. Formation and regeneration of the urothelium , 2014, Current opinion in organ transplantation.
[34] The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma , 2014, Nature.
[35] R. Montironi,et al. HtrA1 in human urothelial bladder cancer: A secreted protein and a potential novel biomarker , 2013, International journal of cancer.
[36] Miriam K. Konkel,et al. A Comparison of 100 Human Genes Using an Alu Element-Based Instability Model , 2013, PloS one.
[37] F. Montorsi,et al. Incidence, survival and mortality rates of stage-specific bladder cancer in United States: a trend analysis. , 2013, Cancer epidemiology.
[38] C. Elferink,et al. The Tumor Suppressor Kruppel-Like Factor 6 Is a Novel Aryl Hydrocarbon Receptor DNA Binding Partner , 2013, The Journal of Pharmacology and Experimental Therapeutics.
[39] John L. Gore,et al. The costs of non-muscle invasive bladder cancer. , 2013, The Urologic clinics of North America.
[40] Benjamin E. Gross,et al. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.
[41] Q. Cui,et al. Identification of the Ah-receptor structural determinants for ligand preferences. , 2012, Toxicological sciences : an official journal of the Society of Toxicology.
[42] Guangchuang Yu,et al. clusterProfiler: an R package for comparing biological themes among gene clusters. , 2012, Omics : a journal of integrative biology.
[43] J. Raufman,et al. Src-mediated aryl hydrocarbon and epidermal growth factor receptor cross talk stimulates colon cancer cell proliferation. , 2012, American journal of physiology. Gastrointestinal and liver physiology.
[44] Benjamin E. Gross,et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.
[45] Bin Zhao,et al. Exactly the same but different: promiscuity and diversity in the molecular mechanisms of action of the aryl hydrocarbon (dioxin) receptor. , 2011, Toxicological sciences : an official journal of the Society of Toxicology.
[46] Dalei Wu,et al. Interaction of aryl hydrocarbon receptor and NF-κB subunit RelB in breast cancer is associated with interleukin-8 overexpression. , 2011, Archives of biochemistry and biophysics.
[47] Matko Bosnjak,et al. REVIGO Summarizes and Visualizes Long Lists of Gene Ontology Terms , 2011, PloS one.
[48] S. Eltom,et al. Malignant transformation of mammary epithelial cells by ectopic overexpression of the aryl hydrocarbon receptor. , 2011, Current cancer drug targets.
[49] Bin Zhao,et al. CH223191 is a ligand-selective antagonist of the Ah (Dioxin) receptor. , 2010, Toxicological sciences : an official journal of the Society of Toxicology.
[50] B. Kaina,et al. The aryl hydrocarbon receptor (AhR) in the regulation of cell-cell contact and tumor growth. , 2010, Carcinogenesis.
[51] H. Kakizaki,et al. Six-transmembrane epithelial antigen of the prostate as an immunotherapeutic target for renal cell and bladder cancer. , 2010, The Journal of urology.
[52] Cancer Facts & Figures 2021 , 2010 .
[53] Ruben Abagyan,et al. Modeling of the aryl hydrocarbon receptor (AhR) ligand binding domain and its utility in virtual ligand screening to predict new AhR ligands. , 2009, Journal of medicinal chemistry.
[54] L. Sheffield. Malignant Transformation of Mammary Epithelial Cells Increases Expression of Leptin and Leptin Receptor , 2008, Endocrine research.
[55] L. Klotz,et al. Lightening up the UV response by identification of the arylhydrocarbon receptor as a cytoplasmatic target for ultraviolet B radiation , 2007, Proceedings of the National Academy of Sciences.
[56] Alessandro Pandini,et al. Structural and functional characterization of the aryl hydrocarbon receptor ligand binding domain by homology modeling and mutational analysis. , 2007, Biochemistry.
[57] Sun-Hee Kim,et al. Novel Compound 2-Methyl-2H-pyrazole-3-carboxylic Acid (2-methyl-4-o-tolylazo-phenyl)-amide (CH-223191) Prevents 2,3,7,8-TCDD-Induced Toxicity by Antagonizing the Aryl Hydrocarbon Receptor , 2006, Molecular Pharmacology.
[58] G. Sauter,et al. High-throughput tissue microarray analysis of COX2 expression in urinary bladder cancer. , 2005, International journal of oncology.
[59] Joshua J. Neumiller,et al. Activation of the aryl hydrocarbon receptor increases pulmonary neutrophilia and diminishes host resistance to influenza A virus. , 2005, American journal of physiology. Lung cellular and molecular physiology.
[60] M. Denison,et al. Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. , 2003, Annual review of pharmacology and toxicology.
[61] A. Hanberg,et al. A constitutively active dioxin/aryl hydrocarbon receptor induces stomach tumors , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[62] J. Jurka,et al. Inverted Alu repeats unstable in yeast are excluded from the human genome , 2000, The EMBO journal.
[63] Y. Fujii‐Kuriyama,et al. Benzo[a]pyrene carcinogenicity is lost in mice lacking the aryl hydrocarbon receptor. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[64] H. Ozen. Bladder cancer. , 1998, Current opinion in oncology.
[65] J. P. Whitlock,et al. DNA Binding by the Heterodimeric Ah Receptor , 1996, The Journal of Biological Chemistry.
[66] Robert C. Wolpert,et al. A Review of the , 1985 .
[67] U. G. Dailey. Cancer,Facts and Figures about. , 2022, Journal of the National Medical Association.